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Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis
through up-regulation of heme oxygenase 1
JENS GAEDEKE, NANCY A. NOBLE, and WAYNE A. BORDER
Fibrosis Research Laboratory, University of Utah, Salt Lake City, Utah; and Med. Klinik m.S. Nephrologie, Charite´, Campus Mitte,
Humboldt Universita¨t, Berlin, Germany
Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis
through upregulation of heme oxygenase 1.
Background. Induction of heme oxygenase 1 (HO-1) has
been shown to be beneficial in a variety of pathologic settings.
Curcumin, a polyphenolic compound, has antifibrotic effects in
lung models of fibrosis, and is known to induce HO-1 in renal
tubular cells. In this study, we determined whether curcumin has
antifibrotic properties in glomerular fibrosis and if these effects
are mediated by induction of HO-1.
Methods. Curcumin effects on HO-1 expression in cultured
mesangial cells and in glomeruli in vivo were analyzed by
Northern and Western blotting. The dose-dependent effect of
curcumin on glomerular fibrosis was tested in the anti-Thy 1
glomerulonephritis model. Curcumin was applied at doses of
10 to 200 mg/kg body weight by intraperitoneal injection from
days 3 to 5 after induction of disease. On day 6, glomeruli
were harvested and markers of fibrosis [plasminogen activa-
tor inhibitor-1 (PAI-1), transforming growth factor-b (TGF-b),
fibronectin, periodic acid-Schiff (PAS) staining] were analyzed.
The effect of HO-1 inhibition was tested in a second experiment
were nephritic rats were treated with curcumin (100 mg/kg body
weight) or the combination of curcumin and the HO-1 inhibitor
zinc protoporphyrin (100 lg/kg).
Results. Curcumin potently induced mesangial cell HO-1 ex-
pression in vitro and up-regulated glomerular HO-1 expression
in nephritic animals in vivo. Curcumin treatment led to a signif-
icant, dose-dependent reduction of markers of fibrosis and pro-
teinuria, with maximal inhibition at doses of 50 to 100 mg/kg.
Beneficial effects of curcumin on markers of fibrosis and pro-
teinuria were lost after HO-1 inhibition.
Conclusion. Curcumin has antifibrotic effects in glomerular
disease, which are mediated through an induction of HO-1.
Chronic renal disease is characterized by the accumu-
lation of extracellular matrix tissue, which is a result of
increased generation and decreased removal of matrix
proteins. The interaction of the cytokines angiotensin
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II and transforming growth factor-b1 (TGF-b1) is of
paramount importance in the regulation of the fibrotic
pathways that ultimately lead to organ malfunction and
organ death [1–3]. Targeting TGF-b directly through anti-
body application [4] or indirectly through inhibition of an-
giotensin II has been shown to reduce the progression of
disease but not completely halt clinical and experimental
chronic renal disease (reviewed in [5]), necessitating the
development of new therapeutic strategies. The polyphe-
nolic compound curcumin has been described as an an-
tifibrotic substance in experimental lung disease [6, 7].
We have previously shown that curcumin blocks TGF-b
effects in cultured renal fibroblasts and mesangial cells
[8], and its effects in pulmonary fibrosis have recently
been shown to be associated with a reduction of TGF-
b [7]. Multiple experimental studies have demonstrated
in vitro and in vivo that curcumin interferes with the
activation of proinflammatory transcription factors like
nuclear factor-kappaB (NF-jB) and activator protein-1
(AP-1) and blocks inflammatory reactions in the lung,
liver, and pancreas [9–12], although the precise mecha-
nism of this anti-inflammatory action remain elusive. One
possibly important effect of curcumin in this regard is its
potential to induce heme oxygenase 1 (HO-1) [13, 14].
Described long ago as an enzyme that metabolizes heme
into biliverdin, iron, and carbon monoxide [15], interest in
this enzyme has increased considerably because of its re-
cently described anti-inflammatory properties. Induction
of HO-1 has been shown to limit inflammatory responses
in the lung [16], liver [17], and kidney [18] by mechanisms
that are not yet fully understood, and it also blocks vascu-
lar, heart, and kidney disease induced by angiotensin II
or at least partially responsive to angiotensin blockade
[19–25]. Since antiangiotensin therapy is the most effec-
tive clinical antifibrotic treatment strategy to date, these
findings prompted us to analyze if curcumin has antifi-
brotic effects in glomerular fibrosis in vivo and if these
effects are due to induction of HO-1. For this we used the
anti-Thy 1 model of glomerulonephritis because of its de-
fined phases of disease, where an inflammatory reaction
that begins hours after induction of disease is followed
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by a fibrotic phase with relatively little inflammatory ac-
tivity. We show that curcumin treatment of rats in the
fibrotic phase of anti-Thy 1 glomerulonephritis leads to a
marked reduction of markers of fibrosis and that this is as-
sociated with an increased HO-1 expression. Blockade of
HO-1 enzyme activity by a specific inhibitor completely
abrogates the beneficial effects of curcumin.
METHODS
Reagents
Curcumin, zinc protoporphyrin, and all other reagents
unless stated differently were from Sigma Chemical Co.
(St. Louis, MO, USA).
In vivo experiments
Induction of anti-Thy 1 glomerulonephritis. The stud-
ies were performed on male Sprague-Dawley rats (100 to
200 g) obtained from the Sasco colony of Charles River
Laboratories (Wilmington, MA, USA). Animal housing
and care were in accordance with the NIH Guide for the
Care and Use of Laboratory Animals (NIH Publication
No. 85-23, 1985). Animals were fed a normal protein diet
(22% protein) (Teklad No. 86 550) (Teklad Premier Lab-
oratory Diets, Madison, WI, USA). Rats were injected
with the monoclonal antibody OX-7 at a dose of 2.2 mg/kg
on day 0 to induce disease.
Treatment protocols
Experiment 1: Dose-dependent effect of curcumin on
parameters of ﬁbrosis. In this experiment, seven groups
of rats (N = 8 to 12) were analyzed: normal control
[phosphate-buffered saline (PBS)-injected]; curcumin
control (injected with 200 mg/kg curcumin); disease con-
trol [antithymocyte serum (ATS) nephritic rats]; and
nephritic rats injected with curcumin at 10, 50, 100, and
200 mg/kg (total daily dose curcumin10 to 200). Curcumin
was dissolved at various concentrations in 70% dimethyl
sulfoxide (DMSO) and a fixed volume of DMSO (500 lL/
day) was given per rat on days 3 to 5 by intraperitoneal
injection. The total daily dose was divided into two injec-
tions given at 12-hour intervals. Animals in the normal
and disease control groups received parallel injections of
70% DMSO alone. The experiment was terminated on
day 6 by harvesting the kidneys after perfusion with ice-
cold PBS. Glomeruli were isolated by a sieving technique
and tubular contamination of suspended glomeruli was
judged by microscopy and was below 5%. After count-
ing, 5000 glomeruli were cultured per well in serum-free
RPMI 1640. After 48 hours, the supernatant was har-
vested and frozen in aliquots at −80◦C.
Experiment 2: Effect of HO-1 inhibition on curcumin-
mediated changes in disease severity. To analyze the role
of HO-1 on the protective effect of curcumin, zinc pro-
toporphyrin was used to block HO-1 enzymatic activity.
Four groups of rats (N = 8 to12) were analyzed: normal
control (PBS-injected); disease control (ATS nephritic
rats); nephritic rats injected with curcumin at 100 mg/kg
(AC); and nephritic rats treated with curcumin (100
mg/kg) and zinc protoporphyrin at 100 lg/kg. The dose of
100 mg/kg of curcumin was chosen because it is the half-
maximal dose of that used in experiment 1 and it had a
more significant effect on matrix accumulation than lower
doses. Curcumin was given as described above, and zinc
protoporphyrin was given in a single intraperitoneal in-
jection at noon from days 3 to 5. Again, the experiment
was terminated on day 6.
Cell culture experiments and HO-1 Western blot
Primary rat mesangial cells derived from male Sprage-
Dawleyrats were used between passages 6 and 10. Cells
were kept in RPMI 1640 with 2 g/L glucose, supple-
mented with penicillin/streptomycin and glutamine so-
lution (Sigma Chemical Co.). Cells were serum-starved
overnight to induce quiescence and subsequently treated
with curcumin (dissolved in 100% ethanol) at the indi-
cated doses and times. Control cells were treated with
100% ethanol alone at a concentration of 1 lL/mL.
Protein samples were harvested with hypotonic lysis
buffer and aliquots were boiled with 4× Laemmli buffer
for 5 minutes, and electrophoresis was performed on
10% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) gels. Blots were stained with
a polyclonal anti-HO-1 antibody (1:1000) (Stressgen,
Vancouver, Canada) for 1 hour at room temperature.
The secondary antibody was from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA), and blots were de-
veloped with the enhanced chemiluminescence (ECL)
reagent from Amersham (Piscataway, NJ, USA). Blots
were also stained with a monoclonal antibody against b-
actin (1:5000) (Sigma Chemical Co.) to control for loading
variations.
For determination of glomerular HO-1 protein content
in experiment 1, aliquots of glomeruli were suspended
in ice-cold lysis buffer right after sieving and were soni-
cated for 2 × 20 seconds on ice. Aliquots were removed
for protein determination and samples were boiled with
Laemmli sample buffer. Western blots were performed
as described above.
HO-1 Northern blotting
Glomerular RNA was harvested with Trizol (Invit-
rogen, Carlsbad, CA, USA). Northern blotting was
performed using Ambion’s Northern Max-Gly System
(Ambion, Austin, TX, USA). A polymerase chain reac-
tion (PCR)–derived HO-1 probe was labeled with P32 us-
ing the Strip-EZ Labeling kit (Ambion) and hybridized
overnight in Ultrahyb hybridization buffer (Ambion).
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After washing, blots were exposed to films which were
scanned and analyzed by densitometry. Optical density
(OD) values were standardized to 18S rRNA bands to
correct for loading variations.
Enzyme-linked immunosorbent assay (ELISA)
measurements
The analysis of plasminogen activator protein-1 (PAI-
1), TGF-b1, and fibronectin released into the supernatant
by cultured glomeruli was performed as previously de-
scribed [26].
Semiquantitative analysis of glomerular matrix protein
accumulation
Periodic acid-Schiff (PAS)–stained slides were blinded
and the percentage of PAS-positive material on glomeru-
lar cross-sections was scored on a scale from 0 (0%) to 4
(75% to 100%) on at least 30 glomeruli per slide.
Proteinuria
Animals were kept in metabolic cages for 24 hours from
days 5 to 6 with full access to food and water. Urinary
protein content was analyzed using the Bradford protein
reagent (Bio-Rad, Hercules, CA, USA) and expressed as
mg/24 hours.
Statistical analysis
Results were analyzed for statistical significance by t
test with Bonferroni correction. A P value of < 0.05 was
regarded as significant.
RESULTS
Effect of curcumin treatment on the production
of mediators of fibrosis (experiment 1)
In experiment 1, we determined whether different
doses of curcumin (10, 50, 100, and 200 mg/kg) had an
effect on mediators of fibrosis in anti-Thy 1 glomeru-
lonephritis. As Figure 1 shows, there is a marked up-
regulation of PAI-1 and TGF-b production in day 6
nephritic glomeruli. Curcumin reduced PAI-1 production
dose-dependently in all tested dose groups and signifi-
cantly reduced TGF-b production at 50 and 200 mg/kg.
Similarly, the increased production of the extracellular
matrix protein fibronectin was also reduced by curcumin
treatment. While there was only a slight but statistically
significant reduction at 10 mg/kg, curcumin reduced the
elevated fibronectin production by almost 50% in the 100
and 200 mg group (Fig. 2).
The accumulation of glomerular matrix proteins was
also measured by semiquantitative analysis of PAS-
stained tissue sections. As Figure 2 shows, curcumin at
doses of 50 mg/kg and higher led to a significant reduc-
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Fig. 1. Curcumin blocks the increased production of plasminogen acti-
vator protein-1 (PAI-1) (A) and transforming growth factor-b (TGFb)
(B) in day 6 nephritic glomeruli. PAI-1 and TGFb were analyzed by
enzyme-linked immunosorbent assay (ELISA) in supernatant of cul-
tured glomeruli. Values are given as means ± SD. ∗P ≤ 0.05 vs. glomeru-
lonephritis alone. Abbreviations are: NC, normal control; CC, curcumin
control; DC, disease control; AC10 to 200, nephritic rats treated with
10 to 200 mg/kg curcumin.
tion by 50% of glomerular matrix protein expansion com-
pared to vehicle-treated nephritic rats.
Effect of curcumin treatment on proteinuria
Proteinuria is invariably associated with glomerular
disease and also found in the anti-Thy 1 model of
glomerulonephritis. As shown in Figure 3, there is a dose-
dependent reduction of proteinuria by curcumin from
more than 150 mg/24 hours in the disease control group
to a minimum of around 50 mg/24 hours in rats treated
with 50 mg/kg of curcumin or higher doses.
Induction of HO-1 in glomerular cells by curcumin
The induction of HO-1 by curcumin has been well doc-
umented in several cell types like endothelial cells or
renal proximal tubular cells. To analyze the effect of cur-
cumin on glomerular cells, we first tested the effect of
curcumin treatment on HO-1 expression in cultured rat
mesangial cells. As Figure 4 shows, curcumin dose- and
time-dependently up-regulates HO-1 protein expression
in mesangial cells. This effect is very potent, as already
very low doses of 0.1 lmol/L curcumin led to a profound
Gaedeke et al: Curcumin blocks ﬁbrosis in ATS 2045
60
40
20
0
4
2
1
3
0
n
g/
m
L
M
at
rix
 s
co
re
NC CC DC 10 50 100 200
AC (mg/kg)
*
*
*
**
*
*
A
B
Fig. 2. Curcumin blocks the increased production of fibronectin (A)
and reduces extracellular matrix accumulation [periodic acid-Schiff
(PAS) staining score] (B) in day 6 nephritic glomeruli. Fibronectin was
measured by enzyme-linked immunosorbent assay (ELISA) of super-
natant of cultured gloms. PAS-stained slides were scored for the semi-
quantitative analysis of glomerular fibrosis. Values are given as means
± SD. ∗P ≤ 0.05 vs. glomerulonephritis alone. Abbreviations are: NC,
normal control; CC, curcumin control; DC, disease control; AC10 to
200, nephritic rats treated with 10 to 200 mg/kg curcumin.
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Fig. 3. Curcumin reduces day 5 proteinuria in anti-Thy 1 glomeru-
lonephritis. Values are given as means ± SD. ∗P ≤ 0.05 vs. glomeru-
lonephritis alone. Abbreviations are: NC, normal control; CC, curcumin
control; DC, disease control; AC10 to 200, nephritic rats treated with
10 to 200 mg/kg curcumin.
increase of HO-1 protein compared to untreated controls.
After induction by curcumin, HO-1 protein remained up-
regulated for more than 24 hours. Curcumin failed to in-
duce HO-2 in rat mesangial cells and did not modulate
HO-1 protein
C 0.1 1 5 7.5 10 2C 4 6 8 24 h
Dose response Time course
µmol/L Curcumin, 8h Curcumin, 10 µmol/L
Fig. 4. Induction of heme oxygenase 1 (HO-1) protein expression in
cultured rat mesangial cells by curcumin. Quiescent cells were treated
with curcumin as shown and HO-1 expression was analyzed using West-
ern blot. The blots show a representative of three to four experiments.
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Fig. 5. Curcumin induces glomerular heme oxygenase 1 (HO-1)
mRNA (A) and protein (B) expression in anti-Thy 1 glomerulonephri-
tis. (A) A Northern blot of pooled samples. (B) A bar graph that sum-
marizes densitometries of Western blots results from individual animals.
Values are given as means ± SD. ∗P ≤ 0.05 vs. glomerulonephritis alone.
constitutive HO-2 expression in a rat endothelial cell line
(RGE, data not shown).
To analyze the effect of curcumin treatment on HO-1
expression in vivo, we performed Northern blots on
glomerular RNA derived from animals analyzed in exper-
iment 1. Figure 5A shows that while HO-1 mRNA is up-
regulated in control nephritic animals, it is superinduced
in nephritic animals treated with curcumin. Figure 5B
shows results from Western blots of glomerular lysates of
individual animals of all groups and confirms a superin-
duction of HO-1 at the protein level by curcumin.
Inhibition of HO-1 enzyme activity abrogates the
protective effects of curcumin (experiment 2)
Using a specific inhibitor of HO-1 (zinc protopor-
phyrin), we analyzed if the protective effect of curcumin
is dependent on HO-1 enzyme activity. As Figure 6 shows,
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Fig. 6. Inhibition of heme oxygenase 1 (HO-1) activity by zinc pro-
toporphyrin blocks the protective effects of curcumin on plasminogen
activator-1 (PAI-1) and transforming growth factor-b (TGF-b) expres-
sion in day 6 nephritic glomeruli. PAI-1 and TGFb were analyzed by
enzyme-linked immunosorbent assay (ELISA) in supernatant of cul-
tured glomeruli. Values are given as means ± SD.∗P ≤ 0.05 vs. glomeru-
lonephritis alone. Abbreviations are: NC, normal control; DC, disease
control; AC, nephritic rats treated with curcumin; ACP, nephritic rats
treated with curcumin and zinc protoporphyrin; n.s., not significant.
curcumin at a dose of 100 mg/kg again potently re-
duced the increased PAI-1 and TGF-b production seen
in day 6 nephritic glomeruli. However, this protective
effect of curcumin was lost by coadministration of zinc
protoporphyrin.
The protective effect of curcumin on the accumula-
tion of extracellular matrix proteins was similarly blocked
by HO-1 inhibition. As Figure 7 shows, fibronectin pro-
duction and glomerular PAS-positive material are signif-
icantly reduced by curcumin treatment and returned to
nephritic control values by HO-1 inhibition.
The analysis of proteinuria in animals treated with the
HO-1 inhibitor shows that the antiproteinuric effect of
curcumin treatment is also dependent on HO-1 enzyme
activity (Fig. 8).
Figure 9 shows the micrographs of PAS-stained slides
of representative glomeruli from normal rats, disease con-
trol rats, and diseased rats that have either been treated
with curcumin alone, or with curcumin and zinc protopor-
phyrin. The slides show that compared to disease control
rats the accumulation of PAS-positive material is reduced
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Fig. 7. Inhibition of heme oxygenase 1 (HO-1) activity by zinc proto-
porphyrin blocks the protective curcumin effects on fibronectin produc-
tion and accumulation of matrix proteins in day 6 nephritic glomeruli.
Fibronectin was measured by enzyme-linked immunosorbent assay
(ELISA) of supernatant of cultured gloms. Periodic acid-Schiff (PAS)–
stained slides were scored for the semiquantitative analysis of glomeru-
lar fibrosis. Values are given as means ± SD. ∗P ≤ 0.05 vs. glomeru-
lonepritis alone. Abbreviations are NC, normal control; DC, disease
control; AC, nephritic rats treated with curcumin, ACP, nephritic rats
treated with curcumin and zinc protoporphyrin; n.s., not significant.
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Fig. 8. Inhibition of heme oxygenase 1 (HO-1) activity by zinc pro-
toporphyrin blocks the protective curcumin effects on proteinuria in
anti-Thy 1 glomerulonephritis. Values are given as means ± SD. ∗P ≤
0.05 vs. glomerulonephritis alone. Abbreviations are: NC, normal con-
trol; DC, disease control; AC, nephritic rats treated with curcumin, ACP,
nephritic rats treated with curcumin and zinc protoporphyrin; n.s., not
significant.
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Fig. 9. Effect of curcumin and curcumin and
zinc protoporphyrin on glomerular matrix
accumulation in periodic acid-Schiff (PAS)–
stained slides. (A) Normal control. (B) Dis-
ease control. (C) Nephritic rats treated with
curcumin. (D) nephritic rats treated with cur-
cumin and zinc protoporphyrin (magnifica-
tion ×200).
in the diseased rats that were treated with curcumin.
Treatment with curcumin and the HO-blocker zinc pro-
toporphyrin results in a histologic picture that is identical
to that of untreated diseased rats, indicating a loss of the
protective effect of curcumin after HO-1 blockade.
DISCUSSION
In this study, we analyzed the protective effect
of curcumin on parameters of fibrosis in anti-Thy 1
glomerulonephritis. Our results show that curcumin
dose-dependently reduces parameters of fibrosis such
as elevated glomerular PAI-1, TGF-b , and fibronectin
production. The antifibrotic effect was also evident by a
reduction of glomerular PAS-positive staining. As a func-
tional parameter of glomerular integrity, proteinuria was
also reduced by curcumin treatment.
The antifibrotic effect of curcumin has so far only been
analyzed in models of pulmonary fibrosis such as the
bleomycin or amiodarone model [6, 7]. In those exper-
iments, curcumin administration was associated with a
reduction in inflammatory mediators, reduced expression
of the profibrotic cytokine TGF-b and a subsequent re-
duction in collagen accumulation. Curcumin has been
shown to block proinflammatory pathways like NF-jB
and AP-1 [9–12, 27, 28], but the precise mechanism of its
antifibrotic effect in vivo beyond the reduction of TGF-b
have so far been elusive. As our study shows, curcumin
has an antifibrotic effect in a model of glomerular fibro-
sis, and curcumin treatment in vitro and in vivo leads
to the induction of HO-1. HO-1 is an intracellular en-
zyme that catalyzes the breakdown of heme. Originally
described as a heat-shock–induced enzyme, it is known to
be induced by a variety of inflammatory cytokines, stress
factors and exogenous compounds [29]. The induction of
HO-1 by curcumin has been reported in several cell types,
including human renal tubular cells and, recently, renal
fibroblasts [13, 14, 30]. The mechanism through which cur-
cumin induces HO-1 has been analyzed in some detail in
cultured cells. In human proximal tubular cells, curcumin-
induced HO-1 expression was attenuated by cotreatment
with an inhibitor of NF-jB, implicating this pathway in
the regulation of HO-1 in this cell type [13]. In a rat renal
tubular cell line (NRK 52E), it was shown that curcumin
induces the activity of the p38 mitogen-activated protein
(MAP) kinase pathway, and blockade of p38 MAP kinase
activity partially reduced HO-1 induction by curcumin
[30]. In addition, activation of a redox-sensitive signal-
ing pathway (Nrf2/Keap) has also been implicated in this
study. Interestingly, there are considerable differences in
the effect of cotreatment with N-acetylcysteine, a radi-
cal scavenger and sulfhydryl (SH) group donor, which
blocks curcumin-induced HO-1 expression in some cells
but not in others. Our own preliminary data suggest that
neither the p38 MAP kinase nor the NF-jB pathway
is involved in curcumin-induced HO-1 expression in rat
mesangial cells. Together, these data could indicate that
there are cell-type specific and probably multiple path-
ways by which curcumin activates HO-1 expression. As
our study shows, curcumin is a potent inducer of HO-1
in mesangial cells in vitro with significant effects already
at 0.1 lmol/L and also elevates glomerular HO-1 ex-
pression in vivo. As shown in Figures 6 to 9, inhibition
of HO-1 enzyme activity abrogates the protective ef-
fect of curcumin on glomerular fibrosis. Thus, the an-
tifibrotic effect of curcumin in our model is dependent
on HO-1 enzyme activity. A beneficial effect of HO-1
induction in models of inflammatory glomerular disease
have been demonstrated by Datta et al [31] and Mosley
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et al [32] in the antiglomerular basement membrane (anti-
GBM) model of proliferative nephritis, where induction
of HO-1 by hemin leads to reduced glomerular inflam-
mation and proteinuria [31, 32].
Earlier, seminal studies by Vogt, Nath, and coworkers
[18] have shown that induction of HO-1 protects renal
tubular cells from acute toxic or hypoxic injury through
anti-inflammatory mechanisms. Our experiments supple-
ment these studies and show that HO-1 expression is not
only anti-inflammatory but also blocks fibrotic changes
in a diseased kidney.
Antifibrotic effects of HO-1 have previously been de-
scribed in lung models of inflammation and fibrosis in-
duced by bleomycin or influenza virus [33, 34]. In these
experiments, HO-1 levels were elevated above normal
by adenovirus-based expression systems. Comparable to
our study, pathologically elevated TGF-b levels were re-
duced as well. In vitro, HO-1 induction has recently been
shown to be antifibrotic in human hepatic myofibroblasts
and to be mediated at least in part by bilirubin, a sec-
ondary HO-1 product [35]. Nevertheless, the exact mech-
anism through which HO-1 and its products block TGF-b
overexpression and fibrosis remains unclear. One possi-
bility is that induction of HO-1 limits the inflammatory
response to injury that often precedes and triggers fibro-
sis. Although the data do not rule out such a phenomenon,
our study was designed to exclude this possibility by ap-
plying curcumin only at later time points in the course
of the disease, when the early inflammatory response has
changed to the later fibrotic phase of the disease. This sug-
gests direct effects of HO-1 products on TGF-b signaling
effects, which still have to be elucidated.
It is important to note that curcumin in vitro induced
HO-1 already at very low doses of 0.1 lmol/L in our study.
This concentration is 50 to 100 times lower than what we
have previously found to be necessary to block the ex-
pression of TGF-b–induced mRNAs and down-regulate
TGF-b receptor II (TGF-bRII) expression in mesangial
cells in vitro, which was observed at concentrations of 5
to 10 lmol/L [8]. Since we did not observe any change
in TGF-bRII expression in this study (data not shown),
it is likely that even the relatively high dose used here
(100 mg/kg body weight ≈ 7 g/70 kg in humans) led to
rather low blood levels of curcumin, possibly because of
extensive first-pass metabolism in the liver. Using newer,
water-soluble preparations of curcumin that presumably
provide higher tissue concentrations after intravenous in-
jection might therefore enhance the antifibrotic effect of
curcumin even further.
Using curcumin to induce long-term HO-1 expression
in vivo might offer some benefits over traditionally used
HO-1 inducers like heavy metals, which might accumu-
late in the body, and hemin, which has recently been
shown to have proinflammatory effects in vitro through
the induction of the chemokine monocyte chemoattrac-
tant protein-1 (MCP-1) [36]. Curcumin is part of the tra-
ditional Indian cooking, and has been given in clinical tri-
als orally in quantities of up to 2000 mg per day without
any apparent side effects [37]. However, it is extensively
metabolized in the intestine [38], and thus has low oral
bioavailability. HO-1 expression has been demonstrated
in human kidney disease and presumably has a protective
role in human renal injury [39, 40]. If HO-1 expression
is modified by curcumin in humans is currently unknown
and warrants further studies.
CONCLUSION
Our study shows that curcumin has antifibrotic proper-
ties in a model of glomerular fibrotic disease in vivo and
that this effect is dependent on induction of HO-1. While
any protective role of HO-1 in human kidney disease has
yet to be demonstrated, our data suggest that curcumin
might be beneficial in chronic human kidney disease.
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